Thomas Papathemelis1, Anton Scharl2, Michael Anapolski3, Elisabeth C Inwald4, Atanas Ignatov4, Olaf Ortmann4, Michael Gerken5, Monika Klinkhammer-Schalke5, Sophia Scharl6. 1. Department of Gynecology and Obstetrics, Klinikum St. Marien Amberg, Amberg, Germany. papathemelis@web.de. 2. Department of Gynecology and Obstetrics, Klinikum St. Marien Amberg, Amberg, Germany. 3. Department Ob/Gyn, University of Witten-Herdecke, KKH Dormagen, Dormagen, Germany. 4. Department of Gynecology and Obstetrics, University Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. 5. Tumor Center, University of Regensburg, Regensburg, Germany. 6. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Ismaninger Straße 22, 81675, Munich, Germany.
Abstract
PURPOSE: Lymph node metastasis is a significant predictive factor for disease recurrence and survival in cervical cancer patients and relevant for therapeutic strategies. We evaluated the clinical value of indocyanine green (ICG) by measuring the sensitivity and negative predictive value of sentinel lymph node mapping compared with the gold standard of complete lymphadenectomy in detecting lymph node metastases for cervical cancer. METHODS: We utilized the near-infrared imaging agent ICG to detect tumor-infested lymph nodes in the pelvis analogue to a classical sentinel lymph node procedure by analyzing data from 20 patients who had undergone surgery for cervical cancer at our institution. A laparoscopic lymph node mapping procedure by means of ICG, followed by a complete pelvic lymphadenectomy with or without paraaortic lymphadenectomy was done in all patients. RESULTS: Histological examination identified seven patients with tumor-positive pelvic nodes, whereas mapping with ICG identified only five of these patients. Detection rate of positive nodes by ICG mapping and false negative rate was 71.4% and 28.6%, respectively; bilateral detection rate was 83.3%. One of the two false negative patients additionally suffered from deep infiltrating endometriosis. CONCLUSIONS: Our results indicate that ICG can identify the relevant pelvic nodes independent of tumor size, provided bilateral detection is achieved and additional, related diseases are excluded. TRIAL REGISTRATION: This trial is registered within the German Clinical Trial Register (DRKS-ID: DRKS00014692).
PURPOSE: Lymph node metastasis is a significant predictive factor for disease recurrence and survival in cervical cancer patients and relevant for therapeutic strategies. We evaluated the clinical value of indocyanine green (ICG) by measuring the sensitivity and negative predictive value of sentinel lymph node mapping compared with the gold standard of complete lymphadenectomy in detecting lymph node metastases for cervical cancer. METHODS: We utilized the near-infrared imaging agent ICG to detect tumor-infested lymph nodes in the pelvis analogue to a classical sentinel lymph node procedure by analyzing data from 20 patients who had undergone surgery for cervical cancer at our institution. A laparoscopic lymph node mapping procedure by means of ICG, followed by a complete pelvic lymphadenectomy with or without paraaortic lymphadenectomy was done in all patients. RESULTS: Histological examination identified seven patients with tumor-positive pelvic nodes, whereas mapping with ICG identified only five of these patients. Detection rate of positive nodes by ICG mapping and false negative rate was 71.4% and 28.6%, respectively; bilateral detection rate was 83.3%. One of the two false negative patients additionally suffered from deep infiltrating endometriosis. CONCLUSIONS: Our results indicate that ICG can identify the relevant pelvic nodes independent of tumor size, provided bilateral detection is achieved and additional, related diseases are excluded. TRIAL REGISTRATION: This trial is registered within the German Clinical Trial Register (DRKS-ID: DRKS00014692).
Authors: Gloria Salvo; Pedro T Ramirez; Charles F Levenback; Mark F Munsell; Elizabeth D Euscher; Pamela T Soliman; Michael Frumovitz Journal: Gynecol Oncol Date: 2017-02-08 Impact factor: 5.482
Authors: Beatrice Cormier; John P Diaz; Karin Shih; Rachael M Sampson; Yukio Sonoda; Kay J Park; Khaled Alektiar; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2011-05-13 Impact factor: 5.482
Authors: D Cibula; N R Abu-Rustum; L Dusek; M Zikán; A Zaal; L Sevcik; G G Kenter; D Querleu; R Jach; A S Bats; G Dyduch; P Graf; J Klat; J Lacheta; C J L M Meijer; E Mery; R Verheijen; R P Zweemer Journal: Gynecol Oncol Date: 2011-11-25 Impact factor: 5.482
Authors: J A de Hullu; E Doting; D A Piers; H Hollema; J G Aalders; H S Koops; H Boonstra; A G van der Zee Journal: J Nucl Med Date: 1998-08 Impact factor: 10.057
Authors: Casper Tax; Maroeska M Rovers; Corine de Graaf; Petra L M Zusterzeel; Ruud L M Bekkers Journal: Gynecol Oncol Date: 2015-09-28 Impact factor: 5.482